Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors | RxWiki

Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

Overview[ - collapse ][ - ]

Purpose	This protocol will study treatment for Ewing sarcoma family of tumors (ESFT) and desmoplastic small round cell tumor (DSRCT). Participants with ESFT will be divided into two treatment groups, A or B, based on tumor characteristics. Group A (standard risk) participants have tumor that is not in the pelvis, has not spread to other parts of the body, and are less than 14 years of age. Because previous clinical trials have shown that standard treatment is very effective for children whose tumors have these characteristics, these participants will receive standard treatment. Group B (high risk) participants are 14 years of age or older or have tumor in the pelvis, or the tumor has spread to other parts of the body. Participants with DSRCT in the abdomen and/or pelvis or with tumor that cannot be removed by surgery alone or has spread to other parts of the body will be included in Group B. Participants in this group are considered high risk because there is a greater chance of tumor recurring following standard treatments currently in use. All participants will be followed and evaluated for 10 years following completion of therapy.
Condition	Desmoplastic Small Round Cell Tumor Ewing Sarcoma of Bone Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Intervention	Drug: vincristine Drug: doxorubicin Drug: cyclophosphamide Drug: ifosfamide Drug: etoposide Drug: temozolomide Drug: temsirolimus Drug: bevacizumab Drug: sorafenib Procedure: surgery Radiation: radiation
Phase	Phase 2
Sponsor	St. Jude Children's Research Hospital
Responsible Party	St. Jude Children's Research Hospital
ClinicalTrials.gov Identifier	NCT01946529
First Received	September 16, 2013
Last Updated	November 13, 2013
Last verified	November 2013

Tracking Information[ + expand ][ + ]

First Received Date	September 16, 2013
Last Updated Date	November 13, 2013
Start Date	November 2013
Estimated Primary Completion Date	November 2029
Current Primary Outcome Measures	Response rate [Time Frame: at 6 weeks after start of therapy (after 2 initial courses)] [Designated as safety issue: No]Response rate will be defined as the proportion of patients who achieved complete response or partial response (CR+PR) using the World Health Organization (WHO) criteria evaluated after two initial courses of temsirolimus, temozolomide and irinotecan in previously untreated patients with high risk ESFT. Participants who are treated in Group B with DSRCT or those who do not receive window therapy will not be included in this analysis.
Current Secondary Outcome Measures	Overall Survival [Time Frame: Maximum of 11 years after the start of therapy] [Designated as safety issue: No]Overall survival (OS) is defined as the time interval from the date on study to the date of death or the date of last follow-up. OS will be estimated using the method of Kaplan-Meier for group A and B participants, respectively. Progression-free survival [Time Frame: Maximum of 11 years after the start of therapy] [Designated as safety issue: No]Progression free survival (PFS) is defined as the time interval from the date on study to the date of disease progression or death or the date if last follow-up. PFS will be estimated using the method of Kaplan-Meier for group A and B participants, respectively. Time to progression [Time Frame: Maximum of 11 years after the start of therapy] [Designated as safety issue: No]Median time to progression of group B patients will be estimated from the Kaplan-Meier curve. Local failure rate [Time Frame: Maximum of 11 years after the start of therapy] [Designated as safety issue: No]Loco-regional failure is defined as the time interval from date of start of local therapy to date of loco-regional failure. Distant failure or death prior to loco-regional failure will be considered competing events in the analyses. The cumulative incidence of loco-regional failure will be estimated using methods described in Kalbfleisch and Prentice.

Descriptive Information[ + expand ][ + ]

Brief Title	Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
Official Title	Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
Brief Summary	This protocol will study treatment for Ewing sarcoma family of tumors (ESFT) and desmoplastic small round cell tumor (DSRCT). Participants with ESFT will be divided into two treatment groups, A or B, based on tumor characteristics. Group A (standard risk) participants have tumor that is not in the pelvis, has not spread to other parts of the body, and are less than 14 years of age. Because previous clinical trials have shown that standard treatment is very effective for children whose tumors have these characteristics, these participants will receive standard treatment. Group B (high risk) participants are 14 years of age or older or have tumor in the pelvis, or the tumor has spread to other parts of the body. Participants with DSRCT in the abdomen and/or pelvis or with tumor that cannot be removed by surgery alone or has spread to other parts of the body will be included in Group B. Participants in this group are considered high risk because there is a greater chance of tumor recurring following standard treatments currently in use. All participants will be followed and evaluated for 10 years following completion of therapy.
Detailed Description	PRIMARY OBJECTIVE: - To estimate the response rate to two initial courses of temsirolimus, temozolomide and irinotecan in previously untreated patients with high-risk Ewing sarcoma family of tumors (ESFT). SECONDARY OBJECTIVES: - To estimate the overall survival and progression-free survival in participants with ESFT treated with these approaches. - To estimate the time to progression in participants with ESFT treated in Group B (high risk). - To estimate the cumulative incidence of local failure following local control paradigm in this trial. Group A: Participants will receive interval compressed (every 2 weeks) alternating courses of chemotherapy with vincristine, doxorubicin, and cyclophosphamide (VDC) and with ifosfamide and etoposide (IE). Doxorubicin will be omitted following a total cumulative dose of 375 mg/m^2. Local control measures (surgery and/or radiation therapy) will be instituted after 6 courses of chemotherapy. Total duration of treatment is approximately 29 weeks. Group B: Participants eligible for the window therapy will receive two courses (21 days duration each) of mTOR inhibitor, temsirolimus, in combination with temozolomide and irinotecan. Irinotecan (20 mg/m^2) will be administered IV on a protracted schedule of daily for 5 days, 2 days off, repeated daily x 5 [(qdx5)x2], temozolomide (100 mg/m^2) PO daily x 5 days and temsirolimus 35 mg/m^2 IV weekly on day 1 and 8. Following window treatment (weeks 1 - 6), participants will proceed to induction chemotherapy (weeks 7 - 33) consisting of interval compressed (every 2 weeks) alternating courses of chemotherapy with vincristine, doxorubicin, and cyclophosphamide (VDC) with ifosfamide and etoposide (IE). Doxorubicin will be omitted following a total cumulative dose of 375 mg/m^2. Local control measures (surgery and/or radiation therapy) will be instituted after 6 courses of induction chemotherapy (week 19). Participants whose tumors respond to window therapy will receive temsirolimus, temozolomide and irinotecan at weeks 29 and 31 in place of ifosfamide and etoposide. Following induction therapy, participants will receive six 21-day courses of maintenance therapy consisting of bevacizumab IV on day 1 and daily oral sorafenib and low-dose cyclophosphamide day 1 through day 21.
Study Type	Interventional
Study Phase	Phase 2
Study Design	Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Condition	Desmoplastic Small Round Cell Tumor Ewing Sarcoma of Bone Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Intervention	Drug: vincristine Dosage and route of administration: Infants < 12 months of age: 0.05 mg/kg IV day 1; participants ≥ 12 months of age: 1.5 mg/m^2 IV day 1 (max. dose 2 mg). Other Names: Oncovin(R)Drug: doxorubicin Dosage and route of administration: Infants < 1 year 2.5 mg/kg continuous infusion (CI) over 48 hours, days 1-2; participants > 1 year of age 75 mg/m^2 CI over 48 hours, days 1-2. Other Names: Adriamycin(R)Drug: cyclophosphamide Dosage and route of administration: The dose and route are different in neo-adjuvant/adjuvant chemotherapy and maintenance therapy. Please see the Detailed Description for further information. Other Names: Cytoxan(R)Drug: ifosfamide Dosage and route of administration: Infants < 1 year of age 60 mg/kg/day IV over 60 minutes days 1-5; participants > 12 months of age 1800 mg/m^2 IV over 60 minutes x 5 days, days 1-5. Other Names: Ifex(R)Drug: etoposide Dosage and route of administration: Infants < 1 year of age 3.3 mg/kg/day IV over 60 minutes days 1-5; children > 1 year 100 mg/m^2 daily IV over 60 minutes days 1-5. Other Names: VP-16 Vepesid(R) Drug: temozolomide Dosage and route of administration: Temozolomide 100 mg/m^2 PO once daily, days 1-5. Other Names: Temodar(R)Drug: temsirolimus Dosage and route of administration: Temsirolimus 35 mg/m^2 IV once day 1 and day 8. Other Names: CCI-779 Torisel^TM Drug: bevacizumab Dosage and route of administration: Bevacizumab 15 mg/kg IV on day 1 every 3 weeks. Other Names: rhumab VEGF Avastin(R) Drug: sorafenib Dosage and route of administration: 90 mg/m^2/dose PO BID Other Names: BAY-43-9006 Nexavar(R) Procedure: surgery If participant meets the criteria, they will have surgical resection of their tumor. Other Names: therapeutic conventional surgeryRadiation: radiation If the participant meets the criteria, participants will receive radiation therapy. Chemotherapy will continue during radiation. Other Names: proton beam radiation therapy external beam radiation therapy brachytherapy
Study Arm (s)	Active Comparator: Group A (Standard Risk) Participants will receive vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide. Doxorubicin will be omitted following a total cumulative dose of 375 mg/m^2. Depending on the size and location of the participant's tumor, they will have surgery alone, radiation alone, or surgery following by radiation.Local control measures (surgery and/or radiation therapy) will be instituted after 6 courses of chemotherapy. Total duration of treatment is approximately 29 weeks. Active Comparator: Group B (High Risk) Participants will receive vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide, irinotecan, temozolomide, temsirolimus, bevacizumab, and sorafenib. Depending on the size and location of the participant's tumor, they will have surgery alone, radiation alone or surgery followed by radiation.

Recruitment Information[ + expand ][ + ]

Recruitment Status	Recruiting
Estimated Enrollment	47
Estimated Completion Date	November 2029
Estimated Primary Completion Date	January 2019
Eligibility Criteria	Inclusion Criteria: - Group A participants must be <14 years of age at time of diagnosis of histologically proven non-pelvic localized newly diagnosed Ewing sarcoma family of tumor (ESFT) involving the bone or soft tissue. - Group B participants must have a diagnosis of histologically proven ESFT involving the bone or soft tissue and at least one of the following: metastatic disease (must be biopsy proven), or pelvic primary, or ≥14 years of age at the time of diagnosis. - OR Group B participants must be newly diagnosed with intra-abdominal, unresectable or metastatic desmoplastic small round cell tumor. Metastatic site must be biopsy proven. - Age must be ≤25 years. - Must have adequate renal function based on age. - Must not have had prior chemotherapy or radiation therapy. Emergent radiotherapy to preserve vital organ function is permitted. Participants who receive emergent radiation will not be eligible for window therapy. - Must have adequate hepatic function defined as total bilirubin ≤3.0 mg/dL. - Must have adequate cardiac function defined as shortening fraction ≥28%. - Females of childbearing potential and males able to father a child must be willing to practice acceptable methods of birth control to prevent pregnancy. - Additional criteria for Group B participants who will receive upfront window therapy (does not apply to participants who opt out of window therapy): - Cytochrome P450 CYP3A4 active agents: Must not be taking any of the following potent CYP3A4 inducers or inhibitors within 1 week prior to study entry: azole antifungals (such as fluconazole, voriconazole, itraconazole, ketoconazole), rifampin, phenytoin, phenobarbitol, carbamazepine, grapefruit juice and St. John's wort. - Must have measurable disease. - Must not have received emergent radiation therapy. - Serum triglyceride level ≤ 300 mg/dL and serum cholesterol ≤ 300 mg/dL. - Random or fasting glucose within the upper limits of normal for age. If random glucose is elevated, fasting glucose must be within normal range. Exclusion Criteria: - Participant is pregnant or breastfeeding. - Inability or unwillingness of research participant or legal guardian/representative to give written informed consent. - Participant has a prior history of malignancy, with the exception of non-melanoma skin cancer. Participants with history of skin cancer must have 5 years elapse since that diagnosis, be in remission, and must not have received chemotherapy, immunotherapy, or radiation therapy.
Gender	Both
Ages	N/A
Accepts Healthy Volunteers	No
Contacts	Contact: Fariba Navid, MD 866-278-5833 info@stjude.org
Location Countries	United States

Administrative Information[ + expand ][ + ]

NCT Number	NCT01946529
Other Study ID Numbers	ESFT13
Has Data Monitoring Committee	Yes
Information Provided By	St. Jude Children's Research Hospital
Study Sponsor	St. Jude Children's Research Hospital
Collaborators	Not Provided
Investigators	Principal Investigator: Fariba Navid, MD St. Jude Children's Research Hospital
Verification Date	November 2013

Locations[ + expand ][ + ]